Literature DB >> 33567524

Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease.

Qiyue Ding1, Nataliia V Shults1, Sergiy G Gychka2, Brent T Harris3, Yuichiro J Suzuki1.   

Abstract

Alzheimer's disease is a chronic neurodegenerative disorder and represents the main cause of dementia globally. Currently, the world is suffering from the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter the host cells. In COVID-19, neurological manifestations have been reported to occur. The present study demonstrates that the protein expression level of ACE2 is upregulated in the brain of patients with Alzheimer's disease. The increased ACE2 expression is not age-dependent, suggesting the direct relationship between Alzheimer's disease and ACE2 expression. Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease, and brains with the disease examined in this study also exhibited higher carbonylated proteins, as well as an increased thiol oxidation state of peroxiredoxin 6 (Prx6). A moderate positive correlation was found between the increased ACE2 protein expression and oxidative stress in brains with Alzheimer's disease. In summary, the present study reveals the relationships between Alzheimer's disease and ACE2, the receptor for SARS-CoV-2. These results suggest the importance of carefully monitoring patients with both Alzheimer's disease and COVID-19 in order to identify higher viral loads in the brain and long-term adverse neurological consequences.

Entities:  

Keywords:  ACE2; Alzheimer’s disease; COVID-19; angiotensin-converting enzyme 2; brain; coronavirus; oxidative stress

Mesh:

Substances:

Year:  2021        PMID: 33567524      PMCID: PMC7914443          DOI: 10.3390/ijms22041687

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  54 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system.

Authors:  Marc F Doobay; Lauren S Talman; Teresa D Obr; Xin Tian; Robin L Davisson; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-08-31       Impact factor: 3.619

Review 3.  Alzheimer's disease.

Authors:  Clive Ballard; Serge Gauthier; Anne Corbett; Carol Brayne; Dag Aarsland; Emma Jones
Journal:  Lancet       Date:  2011-03-01       Impact factor: 79.321

Review 4.  Alzheimer's disease.

Authors:  Philip Scheltens; Kaj Blennow; Monique M B Breteler; Bart de Strooper; Giovanni B Frisoni; Stephen Salloway; Wiesje Maria Van der Flier
Journal:  Lancet       Date:  2016-02-24       Impact factor: 79.321

Review 5.  Proteomic Characterization of Reversible Thiol Oxidations in Proteomes and Proteins.

Authors:  Susanna Boronat; Alba Domènech; Elena Hidalgo
Journal:  Antioxid Redox Signal       Date:  2016-05-20       Impact factor: 8.401

Review 6.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 7.  Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics.

Authors:  D Allan Butterfield; Marzia Perluigi; Rukhsana Sultana
Journal:  Eur J Pharmacol       Date:  2006-06-15       Impact factor: 4.432

Review 8.  Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.

Authors:  Bo Li; Jing Yang; Faming Zhao; Lili Zhi; Xiqian Wang; Lin Liu; Zhaohui Bi; Yunhe Zhao
Journal:  Clin Res Cardiol       Date:  2020-03-11       Impact factor: 6.138

Review 9.  Oxidative stress and the pathogenesis of Alzheimer's disease.

Authors:  Yan Zhao; Baolu Zhao
Journal:  Oxid Med Cell Longev       Date:  2013-07-25       Impact factor: 6.543

10.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

View more
  19 in total

1.  Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT4R) in the postmortem brains of individuals without cognitive impairment.

Authors:  Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Ruth Marx-Rattner; Laura Powell; Qian-Li Xue; Jing Tian; Esther S Oh; Luigi Ferrucci; Pervin Dincer; David A Bennett; Jeremy D Walston; Peter M Abadir
Journal:  Geroscience       Date:  2022-08-15       Impact factor: 7.581

2.  SARS-CoV-2, the Angiotensin Converting Enzyme 2 (ACE2) Receptor and Alzheimer's disease.

Authors:  Walter J Lukiw
Journal:  J Alzheimers Dis Parkinsonism       Date:  2021-05-10

Review 3.  Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.

Authors:  Fernando Bartolomé; Luigi Rosa; Piera Valenti; Francisco Lopera; Jesús Hernández-Gallego; José Luis Cantero; Gorka Orive; Eva Carro
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

4.  Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson's disease.

Authors:  Anna Pierzchlińska; Jarosław Sławek; Monika Mak; Barbara Gawrońska-Szklarz; Monika Białecka
Journal:  Mol Biol Rep       Date:  2021-07-23       Impact factor: 2.316

5.  Levels of Angiotensin-Converting Enzyme and Apolipoproteins Are Associated with Alzheimer's Disease and Cardiovascular Diseases.

Authors:  Chun Xu; Debra Garcia; Yongke Lu; Kaysie Ozuna; Donald A Adjeroh; Kesheng Wang
Journal:  Cells       Date:  2021-12-23       Impact factor: 6.600

6.  Severe COVID-19 in Alzheimer's disease: APOE4's fault again?

Authors:  Nian Xiong; Martin R Schiller; Jingwen Li; Xiaowu Chen; Zhicheng Lin
Journal:  Alzheimers Res Ther       Date:  2021-06-12       Impact factor: 6.982

7.  The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer's Disease Pathology.

Authors:  Huan Cui; Si Su; Yan Cao; Chao Ma; Wenying Qiu
Journal:  Front Cell Dev Biol       Date:  2021-06-25

8.  COVID-19: a novel risk factor for perioperative neurocognitive disorders.

Authors:  Penghui Wei; Wenyuan Lyu; Tiantian Wan; Qiang Zheng; Wenxi Tang; Jianjun Li; Jian-Jun Yang
Journal:  Br J Anaesth       Date:  2021-06-19       Impact factor: 11.719

9.  SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer's Disease Patients.

Authors:  Luigi Chiricosta; Agnese Gugliandolo; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2021-12-19       Impact factor: 5.923

10.  Mitochondrial hijacking: a potential mechanism for SARS-CoV-2 to impair female fertility.

Authors:  Jun Sun; Qiong Liu; Xinling Zhang; Shu Dun; Li Liu
Journal:  Med Hypotheses       Date:  2022-01-25       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.